| 50 -0.02 (-0.04%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 65.39 | 1-year : | 70.78 |
| Resists | First : | 55.99 | Second : | 60.59 |
| Pivot price | 52.47  |
|||
| Supports | First : | 48.54 | Second : | 40.38 |
| MAs | MA(5) : | 49.74 |
MA(20) : | 53.21 |
| MA(100) : | 47.56  |
MA(250) : | 31.22 |
|
| MACD | MACD : | -1.7 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 14.5 |
D(3) : | 12.7 |
| RSI | RSI(14): 39 |
|||
| 52-week | High : | 66.37 | Low : | 14.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ETON ] has closed above bottom band by 24.2%. Bollinger Bands are 17.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 50.86 - 51.11 | 51.11 - 51.31 |
| Low: | 48.07 - 48.4 | 48.4 - 48.68 |
| Close: | 49.52 - 50.04 | 50.04 - 50.46 |
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Fri, 23 Oct 2026
Eton Pharmaceuticals, Inc. Estimates – BOATS:ETON - TradingView
Fri, 23 Oct 2026
Eton Pharmaceuticals Has Stronger Earnings And Little Valuation Cushion (NASDAQ:ETON) - Seeking Alpha
Wed, 07 Oct 2026
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Yahoo Finance
Wed, 30 Sep 2026
Eton Pharmaceuticals (NASDAQ:ETON): High Growth Momentum Meets a Breakout Setup - ChartMill
Fri, 14 Aug 2026
Why Eton Pharmaceuticals Is Top of the Class Today - Yahoo Finance
Fri, 14 Aug 2026
Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 29 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 71 (%) |
| Shares Short | 1,830 (K) |
| Shares Short P.Month | 1,350 (K) |
| EPS | 0.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.64 |
| Profit Margin | 12 % |
| Operating Margin | 35.7 % |
| Return on Assets (ttm) | 11.8 % |
| Return on Equity (ttm) | 35.9 % |
| Qtrly Rev. Growth | 98.5 % |
| Gross Profit (p.s.) | 2.26 |
| Sales Per Share | 3.69 |
| EBITDA (p.s.) | 0.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 15 (M) |
| Levered Free Cash Flow | 7 (M) |
| PE Ratio | 125 |
| PEG Ratio | 0 |
| Price to Book value | 30.3 |
| Price to Sales | 13.53 |
| Price to Cash Flow | 94.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|